Evidence mapPaperPMID 35931285Full record

ReviewRevista espanola de cardiologia (English ed.)2022

Environment and cardiovascular health: causes, consequences and opportunities in prevention and treatment.

Jordi Bañeras, Josep Iglesies-Grau, María Téllez-Plaza, Vicente Arrarte, Néstor Báez-Ferrer, Begoña Benito, Raquel Campuzano Ruiz, Alberto Cecconi, Alberto Domínguez-Rodríguez, Antonio Rodríguez-Sinovas and 4 more

2 registry-linked trialsOpen access · greenAbstract readReview
In one paragraph

Review in Revista espanola de cardiologia (English ed.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00044213 phase3completednot on this map

Trial to Assess Chelation Therapy (TACT)

TypeinterventionalSponsorMt. Sinai Medical Center, MiamiRan2003 to 2012Enrolled1,708ConditionsCoronary Artery DiseaseArmsEDTA, EDTA Placebo, High Dose Vitamin, High Dose Vitamin Placebo
NCT02733185 phase3completednot on this map

Trial to Assess Chelation Therapy 2

TypeinterventionalSponsorMt. Sinai Medical Center, MiamiRan2016 to 2023Enrolled1,000ConditionsDiabetes, Myocardial InfarctionArmsdisodium EDTA, Oral Multi Vitamins/Minerals (OMVM), Placebo disodium EDTA, Placebo Oral Multi Vitamins/Minerals (OMVM)
3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 10 institutions in 3 countries.

Jordi BañerasServei de Cardiologia, Hospital Universitari Vall d'Hebron, Vall d'Hebron Institut de Recerca, Universitat Autònoma de Barcelona, Barcelona, Spain; Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Spain.
Josep Iglesies-GrauCentre ÉPIC and Research Center, Montreal Heart Institute, Montreal, Quebec, Canada.
María Téllez-PlazaCentro Nacional de Epidemiología, Instituto de Salud Carlos III, Madrid, Spain.
Vicente ArrarteServicio de Cardiología, Hospital General Universitario Dr. Balmis, ISABIAL, Alicante, Spain.
Néstor Báez-FerrerServicio de Cardiología, Hospital Universitario de Canarias, Universidad Europea de Canarias, Santa Cruz de Tenerife, Spain.
Begoña BenitoServei de Cardiologia, Hospital Universitari Vall d'Hebron, Vall d'Hebron Institut de Recerca, Universitat Autònoma de Barcelona, Barcelona, Spain; Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Spain.
Raquel Campuzano RuizServicio de Cardiología, Hospital Universitario Fundación de Alcorcón, Alcorcón, Madrid, Spain.
Alberto CecconiServicio de Cardiología, Hospital Universitario de La Princesa, Madrid, Spain.
Alberto Domínguez-RodríguezCentro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Spain; Servicio de Cardiología, Hospital Universitario de Canarias, Universidad Europea de Canarias, Santa Cruz de Tenerife, Spain.
Antonio Rodríguez-SinovasServei de Cardiologia, Hospital Universitari Vall d'Hebron, Vall d'Hebron Institut de Recerca, Universitat Autònoma de Barcelona, Barcelona, Spain; Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Spain.
Francisco UjuetaColumbia University Division of Cardiology, Mount Sinai Medical Center, Miami Beach, Florida, United States.
Carlos VozziDepartamento de Cardiología, Instituto Vozzi, Rosario, Argentina.
Gervasio A LamasColumbia University Division of Cardiology, Mount Sinai Medical Center, Miami Beach, Florida, United States; Department of Medicine, Mount Sinai Medical Center, Miami Beach, Florida, United States.
Ana Navas-AciénDepartment of Environmental Health Sciences, Columbia University Mailman School of Public Health, Nueva York, United States. Electronic address: an2737@cumc.columbia.edu.
Centro de Investigación Biomédica en Red · ESColumbia University · USUniversidad Europea de Canarias · ESHospital General Universitario de Alicante Doctor Balmis · ESHospital Universitario de La Princesa · ESHospital Universitario Fundación Alcorcón · ESInstituto de Salud Carlos III · ESMontreal Heart Institute · CAMount Sinai Medical Center · USUniversitat Autònoma de Barcelona · ES

Funding

Translational Research Support CoreP30ES009089 · COLUMBIA UNIVERSITY HEALTH SCIENCES · 1998 to 2025
$10.8M
Research Experience and Training Coordination CoreP42ES033719 · COLUMBIA UNIVERSITY HEALTH SCIENCES · 2025 to 2025
$2.1M
NIEHS NIH HHS P30 ES009089NIEHS NIH HHS P42 ES033719
6 · The paper itself

Abstract

The environment is a strong determinant of cardiovascular health. Environmental cardiology studies the contribution of environmental exposures with the aim of minimizing the harmful influences of pollution and promoting cardiovascular health through specific preventive or therapeutic strategies. The present review focuses on particulate matter and metals, which are the pollutants with the strongest level of scientific evidence, and includes possible interventions. Legislation, mitigation and control of pollutants in air, water and food, as well as environmental policies for heart-healthy spaces, are key measures for cardiovascular health. Individual strategies include the chelation of divalent metals such as lead and cadmium, metals that can only be removed from the body via chelation. The TACT (Trial to Assess Chelation Therapy, NCT00044213) clinical trial demonstrated cardiovascular benefit in patients with a previous myocardial infarction, especially in those with diabetes. Currently, the TACT2 trial (NCT02733185) is replicating the TACT results in people with diabetes. Data from the United States and Argentina have also shown the potential usefulness of chelation in severe peripheral arterial disease. More research and action in environmental cardiology could substantially help to improve the prevention and treatment of cardiovascular disease.

Indexed as

Cardiovascular DiseasesDiabetes MellitusEnvironmental PollutantsMyocardial InfarctionChelating AgentsChelation TherapyHumansMetalsUnited StatesChelating AgentsEnvironmental PollutantsMetalsAir pollutionCardiología ambientalContaminación atmosféricaEnvironmentEnvironmental cardiologyMaterial particuladoMedioambienteMetalesMetalsParticulate matter

Identifiers

PMID35931285
PMCPMC10266758
OpenAlexW4289527672

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.